Printer Friendly

USPTO grants patent related to human reproductive cloning.

Patent Watch (Washington, DC; 202-547-9359), a public interest oversight group, announced that it had uncovered a patent on human reproductive cloning and any "products" created by that process, theoretically including embryos, fetuses and children. The patent , United States Patent 6,211,429, was granted on April 3, 2001, but went unnoticed until Patent Watch discovered that the claims were applicable to human reproductive coning. The owner of the patent is the University of Missouri, but financial interest in the patent is shared by a Massachusetts biotech company Biotransplant Inc.

Patent Watch also revealed that it had uncovered three pending patents currently before the United States Patent and Trademark Office that cover cloned human embryos and fetuses.

1. Patent application serial number 09/816,971, assigned to Geron Corporation, which claims a "reconstituted animal embryo" described as having "its main use in ... mammalian embryos, particularly ruminant, human, or primate embryos;"

2. Patent application serial number 09/755,204, assigned to the University of Connecticut, claiming any "animal" embryo made by a cloning process; and

3. Patent application serial number 09/828,876, assigned to the University of Massachusetts and exclusively licensed to Advanced Cell Technology, claiming a mammalian "fetus obtained according to" a particularly specified cloning process. This patent application specifically contemplates the use of human tissues derived from cloned human embryos, fetuses, and offspring, for transplantation purposes.

Commenting on the pending patents Patent Watch Project Director Peter DiMauro stated, "In deciding on these patents the PTO will be making an historic decision on the commodification of human life. They should reject these patents as violation of public policy."

Patent Watch says the USPTO has the legal authority under both national and international law to reject patents that offend public morality or order but did not do so in the case of the Missouri patent. Nor does any current Congressional bill on human cloning halt the patenting of the process or its products.

"This is not a slippery slope, rather this an ethical and legal free fall," stated Patent Watch Executive Director Andrew Kimbrell commenting on the Missouri patent. "The Patent Office has become a ghoulish human body shop allowing researchers and corporations to patent and own human body parts, cloning processes and even human life forms," Kimbrell continued.

"The Patent Office and Congress must move quickly to halt this commodification of life and to ban all forms of human cloning," Kimbrell concluded.

Patent Watch is a project of the International Center for Technology Assessment. CTA is a non-profit, bi-partisan organization committed to providing the public with full assessments and analyses of technological impacts on society, and is devoted to fully exploring the economic, ethical, social, environmental and political impacts that can result from the applications of technology or technological systems.
COPYRIGHT 2002 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2002 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:United States Patent and Trademark Office
Comment:USPTO grants patent related to human reproductive cloning.(United States Patent and Trademark Office)(Brief Article)
Publication:BIOTECH Patent News
Article Type:Brief Article
Geographic Code:1USA
Date:May 1, 2002
Previous Article:Boston Scientific announces court decision on stent technology.
Next Article:BioCurex receives patent allowance for cancer detection and treatment.

Related Articles
Animal patenting.
Infigen terminates agreement with Pharming Holding.
Center for Bioethics denounces patenting human cloning.
Advanced Cell Technology revails in cloning patent dispute.
Advanced Cell announces ruling on human applications of nuclear transfer, issuance of patent, and intent to appeal adverse ruling on animal claims.
Advanced Cell expands somatic cell nuclear transfer cellular reprogramming intellectual property portfolio.
New patent suits address groundbreaking techniques.
Start Licensing Grants License Rights to GTC Biotherapeutics.
Start Licensing further strengthens position in cloning industry with new patents new patents announced for methods of cloning livestock from...

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |